Last reviewed · How we verify

Giovana Maria Weckwerth — Portfolio Competitive Intelligence Brief

Giovana Maria Weckwerth pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Surgery with Naproxen Surgery with Naproxen marketed Nonsteroidal anti-inflammatory drug (NSAID) Cyclooxygenase (COX-1 and COX-2) Pain Management / Perioperative Care
Surgery with Naproxen and Esomeprazole Surgery with Naproxen and Esomeprazole marketed NSAID + Proton pump inhibitor combination COX-1/COX-2 (naproxen); H+/K+-ATPase (esomeprazole) Pain management / Gastroenterology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Sanofi · 2 shared drug classes
  2. Amneal Pharmaceuticals, LLC · 1 shared drug class
  3. Bayer · 1 shared drug class
  4. Assaf-Harofeh Medical Center · 1 shared drug class
  5. Azienda USL Reggio Emilia - IRCCS · 1 shared drug class
  6. Bausch & Lomb Incorporated · 1 shared drug class
  7. Amzell · 1 shared drug class
  8. Actavis Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Giovana Maria Weckwerth:

Cite this brief

Drug Landscape (2026). Giovana Maria Weckwerth — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/giovana-maria-weckwerth. Accessed 2026-05-16.

Related